Phase I Trial of S-1153 in Patients With HIV Infection
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To assess the toxicity profile and determine the maximum tolerated dose (MTD), if possible,
of S-1153 administered orally 3 times daily for 14 days. To investigate the clinical
pharmacokinetic parameters for S-1153. To assess anti-HIV activity associated with S-1153
administration through evaluation of CD4 and viral load measurements.